The Novavax COVID-19 vaccine is gaining attention as a potential alternative for individuals with autoimmune conditions and those seeking relief from long COVID symptoms. Unlike mRNA vaccines, Novavax uses proteins instead of mRNA, and data suggests it may have milder side effects.
Erin Kissane, co-founder of the COVID Tracking Project, experienced painful joint aches after an mRNA booster but found Novavax to be a “dramatically different experience.” Studies indicate that Novavax users reported fewer complaints of temporary reactions compared to mRNA vaccines, making it an appealing option for some.
Biologists like Florian Krammer appreciate Novavax’s unique technology, which involves injecting proteins grown within moth cells. Research indicates that Novavax is as safe and effective as mRNA shots, though its late arrival to the vaccine scene has impacted uptake rates.
Despite lower vaccination rates, epidemiologist Daniel Park believes Novavax could appeal to those who experienced discomfort with mRNA shots. A study in Italy suggests that Novavax remains over 50% effective at preventing symptomatic COVID four months post-vaccination, and it may offer milder side effects.
For individuals with long COVID and chronic fatigue syndrome (ME/CFS), the choice of vaccine is crucial. While smaller studies show improvement in symptoms after vaccination, larger studies are needed to confirm these findings. Novavax’s rollout has faced challenges, including unpredictable demand and insurance reimbursement issues.
The uncertainties surrounding the effectiveness of different vaccines, coupled with the bumpy rollout, have led some individuals to experiment with Novavax, hoping for relief from long COVID symptoms. The anecdotal evidence is mixed, with some reporting improvement and others experiencing flares in symptoms. As the search for the most suitable vaccine continues, individuals with long COVID and autoimmune conditions weigh the potential benefits against the risks of another infection.